<DOC>
	<DOCNO>NCT00435929</DOCNO>
	<brief_summary>This 2 arm study assess effect moderate liver impairment pharmacokinetics saquinavir ritonavir steady state follow administration saquinavir/ritonavir 1000mg/100mg po bid HIV patient . Saquinavir/ritonavir administer concomitantly 2 3 active nucleoside reverse transcriptase inhibitor . The study compare group HIV patient without know liver disease group moderate liver disease . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Saquinavir/Ritonavir Liver-Impaired Patients With HIV Infection .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>adult patient , 1865 year age ; HIV infection ; normal liver function , moderate liver disease ( ChildPugh grade B ) ; antiretroviral therapy naive eligible take antiretroviral treatment per treatment guideline , treatment experience least 4 week prior first dose . severe ascites screen , ChildPugh grade C ; acute infection current malignancy require treatment ; take inhibitor CYP3A4 ( exception antiHIV drug ) within 14 day prior first dosing ; take inducer CYP3A4 ( exception antiHIV drug ) within 4 week prior pharmacokinetic evaluation ( day 14 28 ) ; evidence resistance saquinavir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Treatment Naive</keyword>
</DOC>